The consensus on the prevention and correction of hyperglycemia in patients with HR+ HER2- metastatic breast cancer treated with alpelisib
The consensus on the prevention and correction of hyperglycemia in patients with HR+ HER2- metastatic breast cancer treated with alpelisib was developed by the experts of the Russian Association of Endocrinologists and the Russian Society of Clinical Oncology. The consensus contains recommendation o...
Guardado en:
Autores principales: | Natalya V. Mazurina, Elena V. Artamonova, Maria F. Beloyartseva, Ekaterina I. Volkova, Inna P. Ganshina, Ekaterina A. Troshina, Sergey A. Tjulandin, Viacheslav A. Chubenko |
---|---|
Formato: | article |
Lenguaje: | RU |
Publicado: |
IP Habib O.N.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/95b6d9b471d74d51ad5bf1e4d91f076f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data
por: Armaghani AJ, et al.
Publicado: (2020) -
The frequency and spectrum of PIK3CA mutations in patients with estrogen receptor-positive HER2-negative advanced breast cancer residing in various regions of Russia
por: Tatiana N. Sokolova, et al.
Publicado: (2021) -
Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives
por: Chang DY, et al.
Publicado: (2021) -
The virtual forum on the diagnosis and treatment of PIK3CA-mutated metastatic breast cancer. October 16th, 2020. Event review
por: Irina V. Poddubnaya, et al.
Publicado: (2021) -
PIK3CA mutation: changing the paradigm of HR+ HER2-negative metastatic breast cancer therapy. Review of the Novartis Pharma satellite symposium, held as part of a virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer with a PIK3CA gene mutation. April 23, 2021
por: Editorial Board
Publicado: (2021)